Inositol Treatment in Different Type of PCOS Phenotype

Evaluation of the efficacy of inositol treatment in women with PCOS in relation to the phenotype (according to the Rotterdam Criteria)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Polycystic Ovary Syndrome Adnexal Diseases Cysts Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Gonadal Disorders Neoplasms Ovarian Cysts Ovarian Diseases Urogenital Diseases

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Clinica Alma Res

Roma, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

women with PCOS of any phenotype

Exclusion criteria

hormonal treatment (such as contraceptive pill)
use of supplements containing myo-inositol
severe co-morbidities

Treatment and study plan

Myo-Inositol

Dietary Supplement

Myo-inositol (4g/die)

Primary outcomes

Regularization of the menstrual cycle

Time frame: Change from baseline number of women with irregular menstrual cycle at 4 months

Number of women with regular/altered menstrual cycle

Sponsors and collaborators

Lead sponsor

Lo.Li.Pharma s.r.l

Industry

Registry information

Official study title

The Effect of Inositol Treatment in Women With PCOS of Different Phenotype

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2023
First posted: Jan 10, 2023
Registry last updated: May 16, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed